A diagnosis of triple-negative breast cancer is typically made after a biopsy confirms the tumor’s receptor status. Imaging ...

Dr Mark Kris discusses how a small 2015 study with just two nivolumab doses led to a wave of curative-intent trials.

SAN FRANCISCO -- Neoadjuvant chemoradiotherapy with or without the investigational PD-1 inhibitor sintilimab significantly increased pathological complete response (pCR) rates compared with ...

A 44-year-old woman with advanced breast cancer achieved remarkable results with neoadjuvant chemotherapy, leading to a ...

Neoadjuvant chemotherapy with a regimen of gemcitabine-cisplatin for high-risk upper tract urothelial carcinoma (UTUC) resulted in a high rate of downstaging, and should now be considered a new ...

Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials Clinical trials frequently include multiple end points that mature at different times. The initial report, typically ...

We would like to comment on Schuler et al., on their well-designed randomized phase II NEOpredict-Lung study (NCT04205552) which was published in Nature Medicine. The main objective of this study was ...

Laparoscopic-assisted vs open surgery for low rectal cancer: 5-year outcomes of the LASRE randomized clinical trial. Legend: NAC: neoadjuvant chemotherapy; S+AC: surgery plus adjuvant chemotherapy; n: ...

The Neotorch randomized phase III clinical trial was designed to evaluate whether the addition of perioperative toripalimab [programmed cell death 1 (PD-1) inhibitor] to platinum-based chemotherapy ...

Phase I clinical trials remain essential for new drug development, identifying new treatment pathways, and identifying ...